When we look at the literature; although MEK inhibitors and BRAF inhibitors are drugs that are generally used in the treatment of malignant melanoma, the interesting detail in this case is their use in NSCLC [8]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.